+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lymphopenia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023 - Product Image

Lymphopenia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

  • ID: 4847082
  • Report
  • 155 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • CSL Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Grifols SA
  • MORE
Global Lymphopenia Therapeutics Market: About this market

The lymphopenia therapeutics market analysis considers sales from acquired lymphopenia and inherited lymphopenia product segments. Our analysis also considers the sales of lymphopenia therapeutics in Asia, Europe, North America, and ROW. In 2018, the acquired lymphopenia segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising incidence of diseases from various therapy areas such as blood cancer and autoimmune disorders will play a significant role in the acquired lymphopenia segment to maintain its market position. Also, our global lymphopenia therapeutics market report looks at factors such as increasing risk factors for lymphopenia. However, adverse effects associated with therapeutics, high cost of therapeutics, and stringent regulations may hamper the growth of the lymphopenia therapeutics industry over the forecast period.

Global Lymphopenia Therapeutics Market: Overview

Increasing risk factors for lymphopenia

High prevalence of risk factors such as inherited diseases, autoimmune disorders, blood cancer or blood diseases, and infectious diseases such as AIDS has led to the reduction in lymphocyte counts in blood of a patient. This increases the incidence of lymphopenia. Pharmaceutical companies are investing in research and development activities to come up with effective and cost-efficient therapeutic drugs for lymphopenia. The availability of these drugs will lead to the expansion of the global lymphopenia therapeutics market at a CAGR of almost 4% during the forecast period.

Strategic alliances

Vendors are focusing on addressing the issues associated with high cost of research and development activities of therapeutic drugs by collaborating with pharmaceutical companies. They are also expanding their distribution networks by entering strategic alliances with other vendors. As a result, the development and commercialization of advanced therapies and drugs for lymphopenia is increasing. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global lymphopenia therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lymphopenia therapeutics manufacturers, that include AbbVie Inc., Bristol-Myers Squibb Co., CSL Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Grifols SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, and Sanofi.

Also, the lymphopenia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • CSL Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Grifols SA
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Acquired lymphopenia - Market size and forecast 2018-2023
  • Inherited lymphopenia - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS
  • Increasing research in regenerative medicines
  • Strategic alliances
  • Presence of patient assistance programs
PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • CSL Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Grifols SA
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02:
Exhibit 03: Global pharmaceuticals market
Exhibit 04: Segments of global pharmaceuticals market
Exhibit 05: Market characteristics
Exhibit 06: Market characteristics analysis
Exhibit 07: Market segments
Exhibit 08: Market definition - Inclusions and exclusions checklist
Exhibit 09: Market size 2018
Exhibit 10: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 11: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 12: Five forces analysis 2018
Exhibit 13: Five forces analysis 2023
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition - Five forces 2018
Exhibit 20: Product - Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: Acquired lymphopenia - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Acquired lymphopenia - Year-over-year growth 2019-2023 (%)
Exhibit 24: Inherited lymphopenia - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Inherited lymphopenia - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Customer landscape analysis
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Decision framework
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendor landscape analysis
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie Inc. - Vendor overview
Exhibit 54: AbbVie Inc. - Business segments
Exhibit 55: AbbVie Inc. - Organizational developments
Exhibit 56: AbbVie Inc. - Geographic focus
Exhibit 57: AbbVie Inc. - Key offerings
Exhibit 58: AbbVie Inc. - Key customers
Exhibit 59: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 60: Bristol-Myers Squibb Co. - Business segments
Exhibit 61: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 62: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 63: Bristol-Myers Squibb Co. - Key offerings
Exhibit 64: Bristol-Myers Squibb Co. - Key customers
Exhibit 65: CSL Ltd. - Vendor overview
Exhibit 66: CSL Ltd. - Business segments
Exhibit 67: CSL Ltd. - Organizational developments
Exhibit 68: CSL Ltd. - Geographic focus
Exhibit 69: CSL Ltd. - Segment focus
Exhibit 70: CSL Ltd. - Key offerings
Exhibit 71: CSL Ltd. - Key customers
Exhibit 72: Gilead Sciences Inc. - Vendor overview
Exhibit 73: Gilead Sciences Inc. - Business segments
Exhibit 74: Gilead Sciences Inc. - Organizational developments
Exhibit 75: Gilead Sciences Inc. - Geographic focus
Exhibit 76: Gilead Sciences Inc. - Key offerings
Exhibit 77: Gilead Sciences Inc. - Key customers
Exhibit 78: GlaxoSmithKline Plc - Vendor overview
Exhibit 79: GlaxoSmithKline Plc - Business segments
Exhibit 80: GlaxoSmithKline Plc - Organizational developments
Exhibit 81: GlaxoSmithKline Plc - Geographic focus
Exhibit 82: GlaxoSmithKline Plc - Segment focus
Exhibit 83: GlaxoSmithKline Plc - Key offerings
Exhibit 84: GlaxoSmithKline Plc - Key customers
Exhibit 85: Grifols SA - Vendor overview7
Exhibit 86: Grifols SA - Business segments7
Exhibit 87: Grifols SA - Organizational developments
Exhibit 88: Grifols SA - Geographic focus
Exhibit 89: Grifols SA - Segment focus
Exhibit 90: Grifols SA - Key offerings
Exhibit 91: Grifols SA - Key customers
Exhibit 92: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 93: Johnson & Johnson Services Inc. - Business segments
Exhibit 94: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 95: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 96: Johnson & Johnson Services Inc. - Segment focus
Exhibit 97: Johnson & Johnson Services Inc. - Key offerings
Exhibit 98: Johnson & Johnson Services Inc. - Key customers
Exhibit 99: Merck & Co. Inc. - Vendor overview
Exhibit 100: Merck & Co. Inc. - Business segments
Exhibit 101: Merck & Co. Inc. - Organizational developments
Exhibit 102: Merck & Co. Inc. - Geographic focus
Exhibit 103: Merck & Co. Inc. - Segment focus
Exhibit 104: Merck & Co. Inc. - Key offerings
Exhibit 105: Merck & Co. Inc. - Key customers
Exhibit 106: Novartis AG - Vendor overview
Exhibit 107: Novartis AG - Business segments
Exhibit 108: Novartis AG - Organizational developments
Exhibit 109: Novartis AG - Geographic focus
Exhibit 110: Novartis AG - Segment focus
Exhibit 111: Novartis AG - Key offerings
Exhibit 112: Novartis AG - Key customers
Exhibit 113: Sanofi - Vendor overview
Exhibit 114: Sanofi - Business segments
Exhibit 115: Sanofi - Organizational developments
Exhibit 116: Sanofi - Geographic focus
Exhibit 117: Sanofi - Segment focus
Exhibit 118: Sanofi - Key offerings
Exhibit 119: Sanofi - Key customers
Exhibit 120: Validation techniques employed for market sizing
Exhibit 121: List of abbreviations
Exhibit 122: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • CSL Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Grifols SA
  • MORE
The following companies are recognised as the key players in the global lymphopenia therapeutics market: AbbVie Inc., Bristol-Myers Squibb Co., CSL Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Grifols SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the strategic alliances”

According to the report, one of the major drivers for this market is the increasing risk factors for lymphopenia.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of therapeutics.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • CSL Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Grifols SA
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi.
Note: Product cover images may vary from those shown
Adroll
adroll